Biofrontera Inc. (BFRI) vs Satellos Bioscience Inc. (MSLE)

A side-by-side comparison of Biofrontera Inc. and Satellos Bioscience Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Biofrontera Inc. logo
BFRI
Biofrontera Inc.
$12M
$0.92HealthcareDelayed quote: Oct 6, 2026, 11:30 AM EDT
Satellos Bioscience Inc. logo
MSLE
Satellos Bioscience Inc.
$10M
$8.09HealthcareDelayed quote: Oct 6, 2026, 10:58 AM EDT

Total return — BFRI vs MSLE

growth of $100 · dividends reinvested · last 1y
BFRI +8.1% (+8.1%/yr)MSLE +13.7% (+13.7%/yr)MSLE compounded faster over this window
100150200Start $100$108$114
BFRI MSLE

BFRI vs MSLE: by the numbers

  • •BFRI is the larger company ($12M vs $10M market cap).
  • •Both run net losses; MSLE's is the smaller (0.00% vs -13.78% net margin).

Metrics side by side

Valuation

MetricBFRIMSLE
P/S ratio0.26N/A
P/B ratio1.980.17

Profitability

MetricBFRIMSLE
Gross margin84.45%0.00%
Operating margin-21.94%0.00%
Net margin-13.78%0.00%
ROE-106.87%-57.34%
ROIC-32.27%-59.35%

Growth (annualized)

MetricBFRIMSLE
Revenue CAGR (5Y)15.55%N/A

Go deeper

Full BFRI analysisFull MSLE analysisInteractive comparison tool

Dig into the metrics

Biofrontera ROESatellos Bioscience ROEBiofrontera operating marginSatellos Bioscience operating marginBiofrontera revenue growthSatellos Bioscience revenue growthBiofrontera free cash flowSatellos Bioscience free cash flow

Biofrontera & Satellos Bioscience appear in these rankings

Fastest Revenue Growth Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.